Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
...
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Sympathetic Mechanisms in Obesity-Crossover Design
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05312892
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Menarini International Operations Luxembourg SA
- Target Recruit Count
- 277
- Registration Number
- NCT05279807
- Locations
- 🇭🇺
Investigational site, Debrecen, Hungary
Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT05275907
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension
- Conditions
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 480
- Registration Number
- NCT05165251
- Locations
- 🇨🇳
Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT05103332
- Locations
- 🇬🇧
Clinical Trial Site, Torpoint, United Kingdom
🇺🇸Clinical Trials Site, Beverly Hills, California, United States
🇺🇸Clinical Trial site, Winston-Salem, North Carolina, United States
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy
- Conditions
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Registration Number
- NCT04978649
China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Target Recruit Count
- 32000
- Registration Number
- NCT04974138
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳The Affiliated Hospital Of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
China Stroke Primary Prevention Trial 2 for Participants with Hypertension and MTHFR 677 TT Genotype
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Target Recruit Count
- 24000
- Registration Number
- NCT04974151
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China
Benefit of Amlodipine in HRT Cycle for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- University Hospital, Montpellier
- Registration Number
- NCT04954196
Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT04929600
- Locations
- 🇨🇳
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.